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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by a polyglutamine
expansion in huntingtin. There are no treatments that are known to slow the neurodegeneration caused by
this mutation. Mutant huntingtin causes disease via a toxic gain-of-function mechanism and has the propen-
sity to aggregate and form intraneuronal inclusions. One therapeutic approach for HD is to enhance the
degradation of the mutant protein. We have shown that this can be achieved by upregulating autophagy,
using the drug rapamycin. In order to ﬁnd safer ways of inducing autophagy for clinical purposes, we pre-
viously screened United States Food and Drug Administration-approved drugs for their autophagy-stimulat-
ing potential. This screen suggested that rilmenidine, a well tolerated, safe, centrally acting anti-hypertensive
drug, could induce autophagy in cell culture via a pathway that was independent of the mammalian target of
rapamycin. Here we have shown that rilmenidine induces autophagy in mice and in primary neuronal culture.
Rilmenidine administration attenuated the signs of disease in a HD mouse model and reduced levels of the
mutant huntingtin fragment. As rilmenidine has a long safety record and is designed for chronic use, our data
suggests that it should be considered for the treatment of HD and related conditions.
INTRODUCTION
Huntington’s disease (HD) is a devastating neurodegenerative
disorder characterized by progressive motor dysfunction,
dementia and emotional disturbances (reviewed in 1 and 2).
It is inherited in an autosomal dominant manner and its preva-
lence is 5–10 cases per 100 000. The median age of clinical
onset is about 37 years of age and the disease progresses
over time and is invariably fatal 15–20 years after onset. Cur-
rently, there is no therapy that slows degeneration in humans
with this disease.
The HD gene codes for a large highly conserved protein of
numerous apparent functions, huntingtin (1). In affected indi-
viduals, there is an expanded polyglutamine sequence in the
protein due to expansion of a polymorphic trinucleotide
repeat sequence (CAGn) near the 5′ end of the gene (3). The
HD mutation results from more than 35 CAG repeats (4).
An inverse relationship exists between the CAG repeat
number (i.e. glutamine residues) and the age of onset of the
ﬁrst symptoms, with higher repeat numbers associated with
a younger age of onset.
Proteolysis of mutant huntingtin releases a persistent
N-terminal fragment comprising the ﬁrst 100–150 residues
with the expanded polyglutamine sequence. This fragment
forms aggregates with itself and other proteins and is believed
to confer toxicity via a gain-of-function mechanism (5). Thus,
HD pathogenesis is frequently modelled with exon 1 fragments
containing expanded polyglutamine repeats, which form
aggregates and cause toxicity in cell models and in vivo (6).
The pathological hallmark of HD is the gradual atrophy of
the striatum (caudate nucleus and putamen), and it is the
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affected within the striatum (7). However, neuronal loss has
been identiﬁed in many other regions of the brain and cortical
degeneration also occurs in early phases (8). Striatal atrophy
begins more than a decade before motor symptoms develop
and therefore by the time of diagnosis, the striatum may be
atrophied by as much as 50% (9,10). Therefore, the ultimate
goal is to develop therapies that prevent the onset of clinical
symptoms in mutation carriers and slow down disease pro-
gression in post-symptomatic individuals.
One way to slow or attenuate the effects of the HD
mutation may be to enhance the removal of the mutant
protein, because it acts as a toxin. We have previously
shown that mutant huntingtin is cleared by (macro)autophagy,
a ﬁnding that has been subsequently replicated by others
(11,12). The autophagy-lysosomal pathway is a major route
for protein clearance in eukaryotic cells. It involves the for-
mation of double membrane structures (called autophago-
somes) around a portion of cytosol, which then fuse with
lysosomes where their contents are degraded. Our data
suggest that autophagy induction may represent a therapeutic
strategy for neurodegenerative diseases like HD that are
caused by intracytoplasmic aggregate-prone proteins (13).
We found that the rapamycin analogue CCI-779, which
induces autophagy by inhibiting the protein kinase mTOR
(mammalian target of rapamycin), improved behavioural per-
formance and decreased aggregate formation in a mouse
model of HD (14) and in a mouse model of another polyglu-
tamine disease, spinocerebellar ataxia type 3 (15). As rapamy-
cin has non-trivial side effects, our laboratory screened
FDA-approved drugs to identify new autophagy-inducing
pathways (16). This screen revealed clonidine and the related
compound rilmenidine, which are both used for the chronic
treatment of hypertension, as mTOR-independent autophagy
inducers. These compounds act on a2-adrenoceptors and
imidazoline I1 receptors in the brain and in the periphery
(17). Clonidine and rilmenidine are centrally acting antihyper-
tensive agents. They act primarily within the rostral part of the
ventrolateral medulla to reduce sympathic outﬂow to peripheral
organs (18). We decided to use rilmenidine in our in vivo trial,
since, in comparison to the prototypical compound clonidine,
this drug is 30 times more selective for imidazoline receptors
than for a2-adrenoceptors and thus causes fewer adverse
central side effects like sedation or antinociception (19–21).
At equihypotensive doses, rilmenidine causes less bradycardia
and reduction in cardiac output, less sedation and little or
no antinociceptive action compared with clonidine (17).
Rilmenidine is known to get into the brain and mediate its anti-
hypertensive effects in this organ (18). The imidazoline I1
receptor is expressed in regions affected by the HD mutation
in both the rodent and human, including the striatum,
cerebral cortex, hippocampus, ventrolateral medulla and
hypothalamus (22–25).
To examine the effect of rilmenidine in vivo, we used the
N171-82Q mice, which express the ﬁrst 171 amino acids of
mutant huntingtin under the control of the mouse prion promo-
ter, which restricts expression of the protein mainly to the
brain (26). These transgenic mice show a profound phenotype
including loss of motor coordination, tremors, weight loss and
premature death.
RESULTS
Rilmenidine increases autophagy in tissue from wild-type
mice
Our previous studies have demonstrated the ability of rilmeni-
dine to induce autophagy and clear model aggregate-prone
proteins such as mutant huntingtin exon 1 (16). In order to
further conﬁrm the suitability of rilmenidine as a potential
therapeutic for use in HD, we showed that its ability to
induce autophagy was not compromised by the presence of
mutant huntingtin. We assessed autophagosome numbers
using the microtubule-associated protein 1 light chain (LC3)
(27). LC3 is processed post-translationally into LC3-I, then
converted to LC3-II, the only known protein that speciﬁcally
associates with autophagosome membranes (28). LC3-positive
vesicle numbers or LC3-II levels (versus loading control) cor-
relate with autophagosome numbers (27). Stable inducible
PC12 cells expressing either wild-type (23Q) or expanded
polyglutamine (74Q) huntingtin both showed a signiﬁcant
increase in LC3-II when treated with rilmenidine (Fig. 1A
and B).
In order to investigate the in vivo effects of rilmenidine on
autophagy, we measured LC3-II levels in muscle samples
from rilmenidine-treated wild-type mice. As shown in
Figure 1C and D rilmenidine signiﬁcantly increased LC3-II
levels. Not unexpectedly, we saw no obvious change in
LC3-II levels in the brains of treated mice. Previous studies
have demonstrated that the detection of increased LC3-II
levels in the brain is very difﬁcult, as neurons appear to
clear autophagosomes very efﬁciently (29). We therefore
used primary neuronal culture to show that treatment with ril-
menidine increases LC3-II levels (Fig. 1E and F). This also
allowed us to demonstrate that this increase in LC3-II levels
results from an increase in synthesis rather than a decrease
in degradation of autophagosomes, as increased levels were
also seen in the presence of baﬁlomycin A1, an autophagy
inhibitor that blocks autophagosome-lysosome fusion and
therefore LC3-II degradation (27) (Fig. 1E and F).
Further analysis of the effects of rilmenidine on primary
neurons conﬁrmed that rilmenidine does not act to upregulate
autophagy via inactivation of the mTOR pathway. Unlike
rapamycin, which has previously been identiﬁed as a possible
therapeutic due to its upregulation of autophagy, rilmenidine
had no effect on phosphorylation of p70 S6 kinase
(Fig. 1G), S6 protein (Fig. 1H) or 4E-BP1 (Fig. 1I), all down-
stream substrates of mTOR kinase activity.
Rilmenidine improves motor phenotype in HD mice
We have studied the effects of rilmenidine in the N171-82Q
mice, which we have previously used to study rapamycin,
thus allowing a rough comparison of the two drugs. We
chose this mouse model as it does not have the very early
onset of disease seen in the R6/2 mice. Also the N171-82Q
transgene is driven by the mouse prion protein promoter
which results in expression predominantly in the brain, com-
pared with the R6/2 mice where the transgene is expressed
widely in the peripheral tissues, such as muscle which may
effect behaviour on various motor tasks (30). The N171-82Q
mice show obvious motor signs on the rotarod and grip-
Human Molecular Genetics, 2010, Vol. 19, No. 11 2145Figure 1. Rilmenidine enhances autophagy in wild-type mice. (A) Endogenous LC3-II levels were measured in stable inducible PC12 cells 48 h after switching
on expression of either huntingtin exon 1 with 23 polyglutamine repeats (htt-23Q) or 74 polyglutamine repeats (htt-74Q) in the presence or absence of rilme-
nidine (for the ﬁnal 24 h). Actin was used as a loading control. (B) LC3-II levels were measured using ﬂuorescent intensity of the bands by Li-Cor Odyssey.
Results are shown as a percentage of control in each individual cell line (n ¼ 5, ∗P , 0.05 by t-test). The increase in LC3-II levels in rilmenidine treated, htt-74Q
is not signiﬁcantly greater than in htt-23Q treated cells, and possible differences may be due to variations between the clonal cell lines used. (C) LC3-II levels in
muscle lysates from rilmenidine-treated and placebo-treated wild-type mice after 24 weeks of treatment. Western blots were also probed for tubulin as a loading
control (D) Densitometric analysis of LC3-II-levels relative to tubulin. Control condition is set to 100%. Error bars show SEM (∗P ¼ 0.036, t-test, n ¼ 4 for
rilmenidine, n ¼ 5 for control). (E) In cultured primary cortical neurons, LC3-II levels were assessed by western blot. Two exposures are shown to allow com-
parison of weaker bands in non-baﬁlomycin A1-treated lanes (2Baf A1) and stronger bands in baﬁlomycin A1-treated lanes without saturation. (F) Densito-
metric quantiﬁcation of LC3-II levels relative to actin in triplicate experiments. (∗P , 0.05 by t-test). Effect of rilmenidine treatment on phosphorylation of
downstream mTOR targets was investigated by western blotting, (G) phosphorylated p70 S6 kinase levels, (H) phosphorylated S6 ribosomal protein and (I)
phosphorylated 4EBP1. In these experiments, rapamycin treatment was used as a control for the inactivation of mTOR where the effects of treatment can be
clearly seen.
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from about 12 weeks of age. We pre-tested the mice at 4
weeks of age to estimate the baseline motor performances,
in order to ensure that the randomly assigned treatment and
placebo groups (controlled by litter) were not signiﬁcantly
different in sex ratio or in their abilities to perform any of
the tasks.
Rilmenidine treatment then started at 5 weeks of age. Be-
havioural testing began at the age of 12 weeks, when
N171-82Q mice show a clear difference in motor perform-
ances compared with non-transgenic littermates, and mice
were then tested every 2 weeks until death or euthanasia due
to reaching the humane endpoint.
Grip strength. Grip strength was quantiﬁed using a grip
strength meter from 12 to 24 weeks. Rilmenidine-treated
171-82Q mice displayed signiﬁcant improved forelimb grip
strength (Fig. 2A) and all limbs grip strength (Fig. 2B) from
12 to 22 weeks of age. There was no inﬂuence of rilmenidine
treatment on the performance of wild-type mice. Also there
was no difference between the two groups in forelimb or all
limb grip strength before treatment commenced at 4 weeks
of age.
Wire manoeuvre. The wire manoeuvre tests the capacity of the
mice to climb back on a horizontal wire when hung on the wire
by their forelimbs. Rilmenidine-treated 171-82Q mice per-
formed signiﬁcantly better on the wire manoeuvre task from
12until20weeksofage(Fig.3A),andagaintherewasnodiffer-
ence between the two groups before the start of treatment at 4
weeks. Also there was no inﬂuence of rilmenidine treatment
on the performance of wild-type mice (data not shown).
Tremors. The severity of tremors was signiﬁcantly improved
in rilmenidine-treated 171-82Q mice at 16 and 18 weeks of
age, and a trend towards an improvement was also seen at
the age of 12 weeks (Fig. 3B), in comparison to the control
group. Wild-type mice do not demonstrate tremors at these
ages, and rilmenidine treatment did not induce tremors in
wild-type mice (data not shown).
Accelerating rotarod apparatus. The accelerated rotarod
apparatus is a measure of motor coordination and measures
the ability of a mouse to maintain balance on a rotating cylin-
der (rotating towards the mouse). As shown in Fig. 4A, we
found a signiﬁcant inﬂuence of rilmenidine treatment on the
behaviour of wild-type mice in this test. Rilmenidine-treated
wild-type mice spent signiﬁcantly less time on the rotarod at
14–24 weeks of age, and even at 12 weeks a trend towards
a diminished performance was visible. This may be due to
the reported sedative effects of the compound (31).
However, despite the decline in rotarod performance seen in
wild-type mice, rilmenidine-treated 171-82Q mice stayed sig-
niﬁcantly longer on the rotarod than control mice at 12 weeks
of age (Fig. 4B). At later time points (14–24 weeks), we did
not observe a decline in the performance of rilmenidine-
treated 171-82Q mice as observed in the wild-type mice.
Rather, the performance of rilmenidine-treated transgenic
mice was similar to these mice treated with the carrier sub-
stance. At 22 weeks of age, there was again a trend towards
an improved performance of the rilmenidine-treated animals.
Thus, despite the negative effects of this drug on wild-type
performance (probably due to its known sedative effects)
(31), a ‘net improvement’ by rilmenidine in our 171-82Q
mice was observed.
Rilmenidine does not prevent weight loss or premature
death in HD mice
Weight loss is a feature in the N171-82Q mice, possibly due to
a hypermetabolic state (32). Transgenic N171-82Q mice
weighed signiﬁcantly less than wild-type mice from 12
weeks of age and rilmenidine treatment did not have an
effect on body weight in transgenic or wild-type mice
(Fig. 5). The 171-82Q mouse model of HD displays premature
death between 16 and 24 weeks of age, the reason for which is
Figure 2. Rilmenidine improved grip strength in a transgenic mouse model of HD. N171-82Q mice were given rilmenidine ip injections four times a week (tg
Rilm: 4, 12 and 14 weeks, n ¼ 20; 16 weeks, n ¼ 19; 18 weeks, n ¼ 16; 20 weeks, n ¼ 12; 22 weeks, n ¼ 6 and 24 weeks, n ¼ 2) or ip injections with the carrier
substance (tg Con: 4, 12, 14 and 16 weeks, n ¼ 20; 18 weeks, n ¼ 17; 20 weeks, n ¼ 12; 22 weeks, n ¼ 6 and 24 weeks, n ¼ 2) from 5 weeks of age. Wild-type
mice were given rilmenidine or placebo injections with the same frequency (wt Rilm and wt Con, n ¼ 5) (A) Forelimb grip strength in N171-82Q mice at 4
weeks (P ¼ n.s.), 12–18 weeks (P , 0.0001), 20 weeks (P ¼ 0.01), 22 weeks (P ¼ 0.0057) and 24 weeks (P ¼ n.s.) (by t-test). Rilmenidine treatment
had no effect on grip strength in wild-type mice. (B) All limb grip strength in N171-82Q mice at 4 weeks (P ¼ n.s.), 12 weeks (P ¼ 0.002), 14 weeks
(P , 0.0001), 16 weeks (P ¼ 0.0015), 18 weeks (P ¼ 0.0001), 20 weeks (P ¼ 0.01), 22 weeks (P ¼ 0.0129) and 24 weeks (P ¼ n.s.) (by t-test). Error bars
represent SEM.
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on the lifespan of our transgenic 171-82Q mice. Rilmenidine-
treated transgenic mice showed an average lifespan of
148.27+4.62 days (mean+SD), whereas mice treated only
with the carrier substance survived 145.74+4.24 days. Our
survival analysis, however, may be confounded by the fact
that the mice had to be euthanized when their disease severi-
ties exceeded deﬁned humane endpoints to prevent the disease
severity exceeding the UK home ofﬁce moderate category (no
interaction with peers, no righting reﬂexes, major loss of
weight). Thus, we do not know how long the mice would
have survived beyond this point. Furthermore, the cause of
death in these transgenic mice is unknown and is probably
more dependent on metabolic disturbances than on neuronal
pathology (33).
Rilmenidine decreases levels of mutant huntingtin
In order to investigate the effect of rilmenidine treatment on
levels of mutant huntingtin in the brains of transgenic, mice
we measured the levels of the soluble htt-exon1 fragment
using quantitative western blotting methods. A small change
Figure 4. Effect of rilmenidine treatment on rotarod performance of wild-type and transgenic N171-82Q mice. (A) Wild-type mice were given rilmenidine ip
injections (wt Rilm; n ¼ 5) or ip injections with the carrier substance (wt Con; n ¼ 5) four times a week from 5 weeks of age. Performance on the accelerated
rotarod was signiﬁcantly impaired in rilmenidine-treated wild-type mice at 14 weeks (P ¼ 0.0455), 16 weeks (P ¼ 0.0068), 18 weeks (P ¼ 0.0042), 20 weeks
(0.0265), 22 weeks (P ¼ 0.0117) and 24 weeks (P ¼ 0.0141) of age (by t-test). Also a trend towards a diminished rotarod performance was seen at an age of 12
weeks (P ¼ 0.067). Overall effect from all treatment points, P ¼ 0.0007 (repeated measures ANOVA). (B) N171-82Q mice were given rilmenidine ip injections
four times a week (tg Rilm; 4, 12 and 14 weeks, n ¼ 20; 16 weeks, n ¼ 19; 18 weeks, n ¼ 16; 20 weeks, n ¼ 12; 22 weeks, n ¼ 6 and 24 weeks, n ¼ 2) or ip
injections with the carrier substance (tg Con; 4, 12, 14 and 16 weeks, n ¼ 20; 18 weeks, n ¼ 17; 20 weeks, n ¼ 12; 22 weeks, n ¼ 6 and 24 weeks, n ¼ 2) from 5
weeks of age. Rilmenidine-treated N171-82Q mice stayed signiﬁcantly longer on the rotarod than carrier-treated mice at 12 weeks of age (P ¼ 0.0027). However,
there were no signiﬁcant differences at 14,16,18,20 and 24 weeks of age, at 22 weeks there was a trend towards an improvement with rilmenidine treatment( P ¼
0.092) (by t-test).
Figure 3. Rilmenidine treatment improved overall performance at the wire manoeuvre task as well as the severity of tremors at certain time points in N171-82Q
mice. (A) Mice were scored on their ability to perform the wire manoeuvre, score: 0, active grip with hind legs; 1, difﬁculty grasping with hind legs; 2, unable to
lift hind legs; 3, falls within 30 s; 4, falls immediately. The percentage of animals obtaining each score is shown in the graphs, black bars represent rilmenidine-
treated animals and white bars represent control, placebo-treated animals. Signiﬁcant differences between treatment groups were seen at 12 weeks (P ¼ 0.002),
14 weeks (P ¼ 0.017), 16 weeks (P ¼ 0.0246), 18 weeks (P ¼ 0.0211) and 20 weeks (P¼0.0056) of age (Mann–Whitney U test). No signiﬁcant differences
were seen pre-treatment at 4 weeks as well as at 22 weeks (P ¼ 0.1495) of age. (B) The severity of tremors in N171-82Q mice was signiﬁcantly improved
by rilmenidine treatment at 16 weeks (P ¼ 0.0403) and 18 weeks (P ¼ 0.0293) of age, and a trend towards an improvement was also evident at the age of
12 weeks (P ¼ 0.0583) in comparison to the control group. No signiﬁcant differences were seen at 14 weeks (P ¼ 0.1762), 20 weeks (P ¼ 0.2987) and 22
weeks (P ¼ 0.3367) of age. Score: 0, no tremor; 1, mild tremor; 2, severe tremor.
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period of drug treatment (Fig. 6A and B). This is compatible
with a biologically signiﬁcant enhancement of transgene clear-
ance, since this transgene has a long half-life (11).
One of the neuropathological hallmarks of HD is the pres-
ence of aggregates, which are predominantly intranuclear, in
the striatum and deeper layers of the cortex. Immunohisto-
chemistry was performed on coronal sections from
rilmenidine-treated and control HD mice. Aggregates were
counted in three different regions of the brain, the piriform
cortex, motor cortex and hippocampus. The number of aggre-
gates seen was very variable, particularly in the rilmenidine
treated brains, and no alterations in aggregate number were
observed between treatment groups (Fig. 6C and data not
shown). Aggregate size in these sections was also assessed
and the diameter of aggregates showed no change, 0.63+
0.04 mm in placebo versus 0.67+0.04 mm in rilmenidine-
treated mice. The lack of a decrease in aggregate number or
size in brains may be due to the relative availability of the
soluble protein compared with the aggregated protein. As
the aggregates seen in these mice were almost exclusively
nuclear they will be less accessible for degradation by autop-
hagy, which is a cytoplasmic process, unlike the soluble, cyto-
plasmic protein (34). Of relevance, it appears that the large
inclusions visible by light microscopy may be comparatively
protective sequestrations of the more toxic and more soluble
oligomeric species of mutant huntingtin (35). The marked
improvement in behavioural outcome associated with the
decrease in soluble mutant huntingtin seen in these mice is
consistent with this view.
Transient moderate side effects of rilmenidine
Approximately 10 min after ip injection of rilmenidine, we
observed moderate side effects probably related to the
known hypotensive effect of this drug. The mice showed
decreased activity, unsteady gait and some also presented
with hunched posture and piloerection. These side effects
lasted for about 2 h and disappeared completely after 3 h.
We routinely checked the mice 1.5 h post-injection to ensure
that the side effects remained in the moderate severity
category (as deﬁned by the UK Home Ofﬁce) and then
again 3 h post-injection to ensure that all mice had fully recov-
ered. Also we gave transgel as an additional ﬂuid source to
ensure that the mice were always properly hydrated. Neverthe-
less, one rilmenidine-treated transgenic mouse did not comple-
tely recover from its side effects and had to undergo
euthanasia after 10 weeks of treatment, additionally, two
mice treated with rilmenidine for measurement of soluble
protein levels had to be euthanized for the same reason.
Another two mice (one transgenic and one wild-type) had to
undergo euthanasia due to problems related to the repeated
intraperitoneal injections (boils, abdominal signs of infection).
DISCUSSION
The autophagy–lysosomal and ubiquitin–proteasome path-
ways are the major routes for protein degradation in eukaryotic
cells. Whereas the narrow pore of the proteasome barrel pre-
cludes clearance of large protein complexes and intracytoplas-
mic aggregate-prone proteins like mutant huntingtin,
mammalian lysosomes can degrade these by autophagy.
Autophagy is regulated by a number of protein kinases, the
best characterized is mTOR. However, this kinase controls
several cellular processes besides autophagy, which probably
contributes to the complications seen with long-term use of
its inhibitor rapamycin (36). A screen of FDA-approved
drugs revealed the Gi signalling activator clonidine as an
autophagy inducer acting via an mTOR-independent
pathway (16). We also found that the related compound rilme-
nidine increased autophagy in a dose-dependent manner in cell
culture.
We report here that rilmenidine, a drug known to act in the
brain, which is currently used for the chronic treatment of
hypertension, improves behavioural performances in a
variety of domains in a transgenic animal model of HD. The
transgene expression is driven by the mouse prion protein pro-
moter and results in predominantly central nervous system
expression with phenotypes that are widely believed to be
the consequence of neuronal dysfunction. We have assessed
the phenotypes that we have validated as showing clear differ-
ences between the transgenic mice and wild-type littermates
and which all improved with rapamycin treatment in a pre-
vious study (11). We did not assess neuronal cell death as
this does not occur to any overt extent in this mouse model
(26). Also, measurements of brain volume will be difﬁcult to
interpret with autophagy inducers, which might affect this par-
ameter, since the induction of autophagy can reduce cell size
in various cellular and in vivo systems (37,38). The improve-
ment of multiple behavioural parameters throughout the rilme-
nidine treatment period was also associated with a decrease in
the levels of soluble mutant huntingtin. The reduction in the
load of the mutant protein is consistent with at least some of
its effects being due to autophagy. However, the mechanism
of action of rilmenidine could also include other effects
apart from inducing autophagy. Imidazoline drugs, indepen-
dent of their afﬁnity for imidazoline receptors, also interact
(in the micromolar range) with several cation channels,
including N-methyl-D-aspartate (NMDA) receptors. Some
researchers have attributed the neuroprotective effects of
Figure 5. Rilmenidine treatment did not prevent the disease-associated weight
loss in 171-82Q transgenic mice (tg Rilm versus tg Con). The drug also did not
have any inﬂuence on the body weight of wild-type or transgenic mice (wt
Rilm versus wt Con).
Human Molecular Genetics, 2010, Vol. 19, No. 11 2149imidazolines against NMDA-induced neuronal death and
hypoxic insults in vitro to a voltage dependent, fast and
fully reversible blockade of NMDA receptors at a
phencyclidine-like site (36,39).
Unfortunately, there are no ways we can directly show
increased autophagosome synthesis in the brains of mice
treated with rilmenidine in vivo. This is because steady state
levels of autophagosomes in the brain could either increase,
decrease or stay the same, if we induced autophagy (40).
The only way one could show increased autophagosome syn-
thesis would be to clamp autophagosome degradation, some-
thing that is impossible in vivo. However, in order to do this
robustly we have studied the effects of rilmenidine on
primary neuronal culture. The proposed effect on autophagy
is also consistent with the reductions in soluble levels of the
mutant protein we observed in the brains of the treated mice.
The treated mice did show moderate side effects like
reduced activity, unsteady gait and sometimes piloerection
and hunched posture, which lasted for roughly 2 h. This is
probably due to the relatively high doses used in this study
(10 mg/kg intraperitoneally four times a week). Rilmenidine
does bind, albeit with a lower afﬁnity than clonidine, to
alpha2-adrenoceptors and therefore side effects via this recep-
tor cannot be excluded at higher concentrations (41). It is
important to point out that our previous data suggest that ago-
nists acting on either imidazoline or a2-adrenoceptors will
have the same effects on autophagy. Both receptors are Gi
coupled, and agonists of either receptor will reduce cAMP
levels, which we have found to induce autophagy (16). The
deleterious effect of rilmenidine on the rotarod performance
of wild-type mice was not unexpected, as this is seen with
the prototypical compound clonidine in mice (42). Despite
this likely sedative effect observed in rilmenidine-treated wild-
type mice, the rilmenidine-treated 171-82Q mice did not
perform worse than the placebo group on the rotarod, indicat-
ing a net improvement in this test (improvement by the drug
was counteracted by the drug’s sedative effect).
The side effects related to alpha-2 adrenergic agonism may
be tractable in the context of treating HD. First, it is possible
that current doses of rilmenidine that are well tolerated for
treating hypertension, may be sufﬁcient to have beneﬁt over
the many decades it takes for HD to evolve in humans.
Indeed, the excellent tolerability of this drug (reviewed in
43) makes it a suitable candidate drug for delaying the onset
of HD. Since HD is a highly penetrant, autosomal dominant
disease, most cases will have a family history and the mutation
can be easily detected at the DNA level. Thus, it would be
possible to identify HD mutation carriers who are still asymp-
tomatic in order to delay disease onset. Second, compounds
acting exclusively at the imidazoline I1 receptor have been
synthesized (44), and since these are devoid of any
a2-adrenoceptor binding, they may perhaps be more suited
for the long-term treatment of neurodegenerative diseases
with fewer side effects.
In conclusion, our data provide proof-of-principle that ril-
menidine, a centrally acting, well-tolerated drug, can alleviate
the severity of signs in an HD mouse model. The extent of
improvement on grip strength, tremors and wire manoeuvre
seen in HD mice treated with rilmenidine is comparable
with that seen in our previous studies with the autophagy
enhancing drug rapamycin (14). Although there was no
major improvement in rotarod performance in the HD mice
treated with rilmenidine, this can be explained by the side
effect of rilmenidine actually impairing rotarod performance
in wild-type mice. A comparison between the wild-type and
HD mice treated with rilmenidine is compatible with an
overall improvement in rotarod performance mediated by
this drug in HD mice. Thus, we believe that these data and
its very favourable beneﬁt-to-risk proﬁle, suggest that rilmeni-
dine or drugs acting on the same targets as rilmenidine, may be
strong candidates to consider for human trials in HD patients.
MATERIALS AND METHODS
Mouse model
We used HD-N171-82Q mice (B6C3F1/J-Tg(HD82Gln)81
Dbo/J, Jackson Laboratory, Bar Harbour, ME, USA) back-
crossed on a C57BL/6J background for more than 10 gener-
ations. These mice carry an N-terminal fragment expressing
the ﬁrst 171 amino acids of human huntingtin with 82 gluta-
mine repeats under the mouse prion promotor (26).
All studies and procedures were performed under the juris-
diction of appropriate Home Ofﬁce Project and Personal
animal licenses and with local Ethics Committee approval.
Figure 6. Rilmenidine treatment decreases soluble huntingtin levels, but not aggregates. (A and B) Quantiﬁcation of soluble huntingtin levels was carried out by
western blotting with IRDye conjugated secondary antibodies and measurement of ﬂuorescence intensity of the bands corresponding to mutant huntingtin and
actin, as a loading control. Representative lanes from the western blot are shown in (A) and quantiﬁcation is shown in (B) (∗P , 0.05 by t-test, n ¼ 7 for control,
placebo-treated mice and n ¼ 6 for rilmenidine-treated mice, error bars represent SEM). (C) Aggregate number was counted in the motor cortex of control,
placebo-treated and rilmenidine-treated 171-82Q transgenic mice. Aggregates were counted on three sections from three mice in each group (P ¼ n.s. by t-test).
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The litters produced by mating of HD transgenic males with
C57BL/6J females were genotyped at an age of 3 weeks by
PCR, according to the protocol recommended by the




-3′) and HD-591-5′ (5′-GA ACTTTCAGCTACCGAAGAAA
GACCGTGT-3′).
Rilmenidine treatment and behavioural tests
Transgenic mice and non-transgenic littermates were com-
pared in the trial and both genders were used. Mice were
coded with alpha-numeric identities which provided no clues
to their genotype and treated and untreated mice were not
housed in separate cages. Thus observers were blind to their
treatment and genetic status during testing.
Rilmenidine hemifumarate (Tocris Biosciences, Bristol,
UK) was prepared as a stock solution of 10 mg/ml in 20%
ethanol and was diluted on the day of experiment to 1 mg/
ml in 0.15 M NaCl, 5% Tween-20 and 5% PEG 400 immedi-
ately before injection.
We used 20 HD-transgenic mice for rilmenidine treatment
as well as the same number of transgenic animals for the
control group. For studies of the effects of rilmenidine on be-
havioural parameters, we included ﬁve rilmenidine-treated
wild-type mice as well as ﬁve control wild-type mice. There
was no difference in the male:female ratios of the groups
treated with placebo or rilmenidine.
At 4 weeks of age, a pre-assessment of motor performances
was performed. There were no signiﬁcant differences in test
performances in the mice assigned to the treatment and
placebo groups at 4 weeks and no differences in the sex
ratios in the groups.
Rilmenidine treatment was started at an age of 5 weeks.
The mice were weighed and received intraperitoneal
injections (10 mg/kg body weight rilmenidine) four times a
week (Monday, Tuesday, Thursday and Friday). The control
group received ip injections with the carrier substance (0.15 M
NaCl, 5% Tween-20 and 5% PEG 400 and 2% ethanol). Mice
were monitored daily. We chose this dose since 10 mg/kg was
reported not to cause overt sedation (18).
Weassessedmotorperformanceat12,14,16,18,20,22and24
weeks of age with a rotarod apparatus (Accelerating Model, Ugo
Basile, Biological Research Apparatus, Varese, Italy). The mice
weregiventrainingsessionsfor2consecutivedaystoacclimatize
them to the apparatus and on the third day, the deﬁnitive testing
took place. On the ﬁrst training day, the mice had three trials at
a constant speed of 4 r.p.m. In each trial, the animals were put
on the Rotarod for a maximum of 300 s. On the second day,
the training took place at a constant speed of 10 r.p.m. (three
trials).Day3wasthetestingday,wherethespeedwasaccelerated
from 3 to 30 r.p.m. in 300 s. A minimum of 10 min break was
given between each trial. The latency to fall was taken as the
maximum value reached over the three trials.
Grip strength, wire manoeuvre and tremor monitoring was
also performed at 12, 14, 16, 18, 20, 22 and 24 weeks of
age. Grip strength was monitored quantitatively by using a
grip strength meter (Biosep, France). The mice were held
above the apparatus grid with their front paws (forelimb
grip) or all four paws (all limb grip) grasping the grid, then
pulled back by the tail following the axle of the sensor, hori-
zontally and steadily, until they released the grid. The appar-
atus was used in peak mode, the recorded value
corresponding to the maximum force developed by the
animal. Forelimb grip strength as well as all paw grip strength
was measured three times and the average value was taken.
Wire manoeuvre and tremor are part of the SHIRPA battery
of behavioural tests (45). For tremors, the mice were placed
on a grid in a clear perspex cylinder. We recorded tremor
for 2 min and scored the mice as follows: 0, none; 1, mild;
2, marked. For the wire manoeuvre, mice were held above a
horizontal wire by the tail and lowered to allow the forelimbs
to grip the wire. The mice were held in extension, rotated
around the horizontal and released. We scored them as
follows: 0, active grip with hind legs; 1, difﬁculty grasping
with hind legs; 2, unable to grasp with hind legs; 3, unable
to lift hind legs, falls within 10 s; 4, falls immediately.
The following signs were used as humane endpoints for the
mice, which resulted in euthanasia: marked loss of appetite
and ﬂuid intake, staring coat, hunched posture and subdued
behaviour, or 20% weight loss over a period of less than
3 days.
Cell culture and treatment
For assessment of autophagy in primary cells, cortical neurons
were isolated from embryonic day 16.5 Sprague–Dawley rat
pups (Charles River). Brieﬂy, pup brains were harvested and
placed in ice-cold DMEM medium where the meninges were
removed; the cerebral cortices were dissected and then incu-
bated in DMEM containing Accutase (Innovative Cell Tech-
nologies, San Diego, CA, USA) for 10 min at 378C. After
mechanical dissociation using sterile micropipette tips, disso-
ciated neurons were resuspended in DMEM medium and cen-
trifuged. Cell count and viability assay was performed using
Trypan blue. Viable cells were seeded on poly-D-lysine and
laminin coated 6-multiwell (7.5 × 10
5 cells per well). Cells
were maintained in DMEM containing 2 mM glutamine, 2%
B27 supplement and 1% PSF (Invitrogen). One-half of the
plating medium was changed every third day until treatment.
After 7 days in vitro, cultured neurons were treated for 8 h
with 1 mM rilmenidine or 0.2 mM rapamycin (Sigma-Aldrich).
Where used, a saturating concentration (400 nM) of baﬁlomy-
cin A1 (Calbiochem) was added to the cells in the last 4 h
before harvesting. The stable inducible PC12 cells have been
previously described (11), cells were treated with doxycycline
to induce huntingtin expression for 24 h at 1 mg/ml with the
addition of 1 mM rilmenidine for a further 24 h and baﬁlomy-
cin A1 as for primary neurons.
Protein extraction and western blot analysis
Mouse muscle samples from rilmenidine- or placebo-treated
wild-typemice(fourrilmenidine-treatedandﬁveplacebo-treated
mice) at an age of 28 weeks were homogenized in lysis buffer
[10 mM Tris–HCl, pH 6.8, 68.5 nM NaCl, 0.5 mM EGTA,
Human Molecular Genetics, 2010, Vol. 19, No. 11 21510.5% Triton X-100, 5% glycerol and protease inhibitor cocktail
(Roche Diagnostics)] at 48C. For brains, the lysis buffer was
50 mM Tris, pH 7.4, 5.5% Triton X-100 and protease inhibitor
cocktail. The homogenate was centrifuged at 13 400g at 48C,
the supernatant was removed and used for western blot. Cell
pellets were lysed on ice in Laemmli buffer [6.5 mM Tris–
HCl pH 6.8, 2% sodium dodecyl sulphate (SDS), 5%
b-mercaptoethanol, 10% glycerol, 0.01% Bromophenol blue
and protease inhibitors) for 30 min. Proteins were separated
on 12% SDS–polyacrylamide gels and transferred onto PVDF
membranes(HybondECLmembrane,AmershamBiosciences).
Membraneswereblockedbyincubationin5%driedmilkinPBS
and 0.1% Tween-20, pH 7.6. The primary antibodies used were
anti-polyglutamine (1C2, Chemicon), anti-LC3 (Novus), anti-
phosphorylated and total 4E-BP1, S6 kinase and S6 protein
(all Cell Signaling), anti-tubulin and anti-actin (Sigma).
Horseradishperoxidase-conjugatedantibodies(AmershamBio-
sciences, 1:2000) were then added and immunoreactive bands
were detected with enhanced chemiluminescence reagent
(ECL, Amersham Biosciences). Quantiﬁcation of western
blotswascarriedoutusingImageJsoftwareandbandintensities
were normalized to actin or tubulin levels. P-values were deter-
mined using unpaired t-tests. For quantiﬁcation of soluble hun-
tingtin levels in rilmenidine-treated mouse brains, protein was
extracted from seven placebo-treated mice and six rilmenidine-
treated mice as above. For analysis of these levels and those of
LC3-II levels in PC12 cells treated with rilmenidine, western
blots were probed with secondary antibodies conjugated to
IRDyew for detection at 780 or 680 nm (Li-Cor Biosciences)
and visualized and quantiﬁed using an Odyssey imaging
system (Li-Cor Biosciences).
Immunohistochemistry
Thirty micrometer sections of rilmenidine-treated and control
transgenic HD mice were analysed for neuronal inclusions
according to the protocol of Davies et al.( 46). Sections
were labelled with anti-huntingtin antibody by free-ﬂoating
immunohistochemistry (EM48, Chemicon). Staining was per-
formed by peroxidase labelling using Vectastain Avidin:Bioti-
nylated enzyme complex (ABC) kit and visualized with DAB
reagent (Vector Laboratories).
Inclusions were counted in the piriform cortex, motor cortex
and hippocampus in three ﬁelds on at least three sections per
animal at a magniﬁcation of ×100 (Zeiss Axioskop2, ﬁeld
diameter 0.2 mm). Aggregates were photographed and diam-
eter measured using Zeiss axiovision software.
Statistics
Signiﬁcancelevelsforcomparisonsbetweengroupsweredeter-
mined with t-tests, repeated measure or factorial ANOVA,
where appropriate, for parametric data and with Mann–
WhitneyUtestsfornon-parametricdata,usingtheSTATVIEW
software, version 4.53 (Abacus Concepts, Berkeley, CA, USA).
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